Centrum Medycyny Oddechowej Mroz Sp. j.

The centre focuses on asthma across its severity spectrum, aiming to test innovative therapies that lower exacerbation risk and improve lung function.

• Evaluation of oral agents for moderate‑to‑severe uncontrolled asthma
• Comparison of inhaled triple therapy versus dual bronchodilator regimens in severe asthma
• Assessment of biologics targeting eosinophilic pathways to reduce severe attacks
• Long‑term safety monitoring of novel monoclonal antibodies in high‑risk asthma patients

These studies, conducted at the Bialystok facility, support patients seeking advanced treatment options for difficult‑to‑control asthma.

Research at the site addresses chronic obstructive pulmonary disease by evaluating new drug combinations and anti‑inflammatory strategies to lessen exacerbations.

• Triple inhaler therapy versus dual bronchodilator outcomes in chronic obstructive pulmonary disease
• IL‑33 inhibition with itepekimab to reduce COPD flare‑ups
• Add‑on inhaled corticosteroid/LABA/LAMA regimens for former smokers with moderate‑to‑severe chronic obstructive pulmonary disease
• Evaluation of novel molecules such as AZD6793 for exacerbation rate reduction in chronic obstructive pulmonary disease

The programme includes long‑term safety extensions, providing valuable data for individuals living with chronic obstructive pulmonary disease.

The centre investigates therapies aimed at slowing disease progression in patients with idiopathic pulmonary fibrosis.

• Antifibrotic agents assessed for preservation of lung volume in idiopathic pulmonary fibrosis
• Measurement of forced vital capacity decline to gauge treatment impact
• Safety and tolerability profiling of novel investigational compounds in idiopathic pulmonary fibrosis cohorts

Findings from these trials help refine therapeutic options for those diagnosed with idiopathic pulmonary fibrosis at the Bialystok clinic.

Focused studies target non‑cystic fibrosis bronchiectasis, seeking to lessen infection‑driven worsening and improve quality of life.

• Anti‑IL‑33 monoclonal antibody (itepekimab) to lower exacerbation frequency in bronchiectasis
• Inhaled nitric oxide formulation (RESP30X) for patients with high‑titer pathogenic microbes
• Evaluation of novel antibiotics and adjunct therapies to manage chronic infections in bronchiectasis

The research supports patients with bronchiectasis by exploring treatments that address both inflammation and bacterial colonisation.

Clinical work at the centre includes trials for pulmonary sarcoidosis, aiming to assess disease‑modifying agents and monitor systemic involvement.

• Long‑term safety of monoclonal antibody XTMAB‑16 in pulmonary sarcoidosis with or without extra‑pulmonary manifestations
• Biomarker and imaging evaluation to track disease activity during treatment
• Comparative effectiveness of immunomodulatory therapies for organ‑specific outcomes

These efforts at Centrum Medycyny Oddechowej Mroz enhance therapeutic choices for individuals affected by pulmonary sarcoidosis.